share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  04/26 16:06
Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the U.S. Securities and Exchange Commission on April 26, 2024. The report announces the departure of Dr. Bankole A. Johnson from the company. On April 24, 2024, Adial Pharmaceuticals entered into a Separation Agreement with Dr. Johnson, which includes a one-time separation fee of $54,375. Additionally, the company may engage Dr. Johnson for consulting services at a rate of $850 per hour and he may be eligible for payments under the company's grant incentive plan related to the development of AD04, with potential payments up to $225,000 upon achieving certain milestones by December 31, 2024. The agreement also features a general release of all claims against the company and a mutual non-disparagement clause. The full text of the Separation Agreement is attached to the report as Exhibit 10.1.
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the U.S. Securities and Exchange Commission on April 26, 2024. The report announces the departure of Dr. Bankole A. Johnson from the company. On April 24, 2024, Adial Pharmaceuticals entered into a Separation Agreement with Dr. Johnson, which includes a one-time separation fee of $54,375. Additionally, the company may engage Dr. Johnson for consulting services at a rate of $850 per hour and he may be eligible for payments under the company's grant incentive plan related to the development of AD04, with potential payments up to $225,000 upon achieving certain milestones by December 31, 2024. The agreement also features a general release of all claims against the company and a mutual non-disparagement clause. The full text of the Separation Agreement is attached to the report as Exhibit 10.1.
Adial Pharmicals, Inc. 是一家在纳斯达克资本市场上市的特拉华州注册公司,交易代码为ADIL,该公司已于2024年4月26日向美国证券交易委员会提交了8-K表格。该报告宣布班科尔·约翰逊博士离开该公司。2024年4月24日,Adial Pharmicals与约翰逊博士签订了分离协议,其中包括54,375美元的一次性离职费。此外,公司可能聘请约翰逊博士以每小时850美元的费率提供咨询服务,根据公司与AD04开发相关的赠款激励计划,他可能有资格获得付款,在2024年12月31日之前实现某些里程碑后,可能的补助金最高可达22.5万美元。该协议还规定全面解除对公司的所有索赔,并附有相互不贬损条款。分居协议的全文作为附录10.1附在报告中。
Adial Pharmicals, Inc. 是一家在纳斯达克资本市场上市的特拉华州注册公司,交易代码为ADIL,该公司已于2024年4月26日向美国证券交易委员会提交了8-K表格。该报告宣布班科尔·约翰逊博士离开该公司。2024年4月24日,Adial Pharmicals与约翰逊博士签订了分离协议,其中包括54,375美元的一次性离职费。此外,公司可能聘请约翰逊博士以每小时850美元的费率提供咨询服务,根据公司与AD04开发相关的赠款激励计划,他可能有资格获得付款,在2024年12月31日之前实现某些里程碑后,可能的补助金最高可达22.5万美元。该协议还规定全面解除对公司的所有索赔,并附有相互不贬损条款。分居协议的全文作为附录10.1附在报告中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息